Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Ocular Therapeutix (OCUL) Accumulated Depreciation & Amortization (2016 - 2024)

Historic Accumulated Depreciation & Amortization for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $27.5 million.

  • Ocular Therapeutix's Accumulated Depreciation & Amortization rose 1645.23% to $27.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $27.5 million, marking a year-over-year increase of 1645.23%. This contributed to the annual value of $27.5 million for FY2025, which is 1645.23% up from last year.
  • As of Q4 2025, Ocular Therapeutix's Accumulated Depreciation & Amortization stood at $27.5 million, which was up 1645.23% from $23.6 million recorded in Q4 2024.
  • Ocular Therapeutix's 5-year Accumulated Depreciation & Amortization high stood at $27.5 million for Q4 2025, and its period low was $15.2 million during Q4 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $20.3 million (2023), whereas its average is $20.8 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 1893.48% in 2021, then surged by 1361.87% in 2022.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Accumulated Depreciation & Amortization stood at $15.2 million in 2021, then increased by 13.62% to $17.3 million in 2022, then increased by 17.26% to $20.3 million in 2023, then rose by 16.64% to $23.6 million in 2024, then increased by 16.45% to $27.5 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $27.5 million for Q4 2025, versus $23.6 million for Q4 2024 and $20.3 million for Q4 2023.